NMIBC Treatment Landscape
Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Janet Kukreja, MD, MPH, FACS
CME Available: auau.auanet.org/node/44076
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Johnson & Johnson
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs.
2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence.
3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.
All content for AUAUniversity is the property of American Urological Association and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
NMIBC Treatment Landscape
Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Janet Kukreja, MD, MPH, FACS
CME Available: auau.auanet.org/node/44076
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Johnson & Johnson
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs.
2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence.
3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.
Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists (Republished)
AUAUniversity
1 hour 9 minutes 56 seconds
5 months ago
Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists (Republished)
Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists (Republished)
CME Available: auau.auanet.org/node/42040
After participating in this CME activity, participants will be able to:
1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy.
2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes.
3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma.
4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management.
5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes.
Acknowledgements
Support provided by an independent educational grant from:
Astellas and Pfizer, Inc.
AUAUniversity
NMIBC Treatment Landscape
Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Janet Kukreja, MD, MPH, FACS
CME Available: auau.auanet.org/node/44076
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Johnson & Johnson
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs.
2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence.
3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.
